Drifts in ADCC-related quality attributes of Herceptin®: Impact on development of a trastuzumab biosimilar

A biosimilar product needs to demonstrate biosimilarity to the originator reference product, and the quality profile of the latter should be monitored throughout the period of the biosimilar's development to match the quality attributes of the 2 products that relate to efficacy and safety. For...

Descrición completa

Gardado en:
Detalles Bibliográficos
Publicado en:MAbs
Main Authors: Kim, Seokkyun, Song, Jinsu, Park, Seungkyu, Ham, Sunyoung, Paek, Kyungyeol, Kang, Minjung, Chae, Yunjung, Seo, Heewon, Kim, Hyung-Chan, Flores, Michael
Formato: Artigo
Idioma:Inglês
Publicado: Taylor & Francis 2017
Assuntos:
Reports
Acceso en liña:https://ncbi.nlm.nih.gov/pmc/articles/PMC5419076/
https://ncbi.nlm.nih.gov/pubmed/28296619
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1080/19420862.2017.1305530
Tags: Engadir etiqueta
Sen Etiquetas, Sexa o primeiro en etiquetar este rexistro!

Títulos similares